Detalles de la búsqueda
1.
Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial.
Ann Oncol
; 29(12): 2371-2378, 2018 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30346481
2.
Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma.
Ann Oncol
; 26(12): 2457-63, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26386123
3.
Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B.
ESMO Open
; 9(6): 103466, 2024 Jun 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38838498
4.
Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer.
Invest New Drugs
; 31(6): 1547-58, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24091982
5.
Clinical Trial Simulations From a Model-Based Meta-Analysis of Studies in Patients With Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy.
CPT Pharmacometrics Syst Pharmacol
; 5(5): 274-82, 2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27299940
6.
Anti-idiotypic response to antigrowth factor receptor monoclonal antibodies.
Eur J Cancer
; 32A(3): 498-505, 1996 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-8814698
7.
Predicting the maximum-tolerated dose of PNU-159548 (4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin) in humans using CFU-GM clonogenic assays and prospective validation.
Eur J Cancer
; 39(5): 675-83, 2003 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-12628848
8.
Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours.
Eur J Cancer
; 38(18): 2407-15, 2002 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-12460785
9.
Ovarian carcinoma therapy with monoclonal antibodies.
Hybridoma
; 12(5): 501-7, 1993 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-8300122
10.
Unidirectional potentiation of binding between two anti-FBP MAbs: evaluation of the involved mechanisms.
J Cell Biochem
; 58(1): 47-55, 1995 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-7642722
11.
In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody.
Br J Cancer
; 72(4): 928-33, 1995 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-7547242
12.
Anti-tumor efficacy of an anti-epidermal-growth-factor-receptor monoclonal antibody and its F(ab')2 fragment against high- and low-EGFR-expressing carcinomas in nude mice.
Int J Cancer
; 62(5): 643-50, 1995 Sep 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-7665239
13.
Efficiency of T cell triggering by anti-CD3 monoclonal antibodies (mAb) with potential usefulness in bispecific mAb generation.
Cancer Immunol Immunother
; 44(5): 257-64, 1997 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-9247560
14.
A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study.
Br J Cancer
; 82(4): 767-71, 2000 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-10732743
15.
Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival.
Int J Cancer
; 84(1): 62-8, 1999 Feb 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-9988234
Resultados
1 -
15
de 15
1
Próxima >
>>